Oxford COVID-19 Vaccine Less Effective Against South African Variant: Study


2021-02-06 23:10:40

Oxford Covid Vaccine Less Effective Against South African Variant: Study

The newspaper said none of the more than 2,000 trial participants had been hospitalised or died. (File)

British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial.

The study from South Africa’s University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day.

Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others.

“In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant,” an AstraZeneca spokesman said in response to the FT report.

The newspaper said none of the more than 2,000 trial participants had been hospitalised or died.

“However, we have not been able to properly ascertain its effect against severe disease and hospitalisation given that subjects were predominantly young healthy adults,” the AstraZeneca spokesman said.

The company said it believed its vaccine could protect against severe disease, given that the neutralising antibody activity was equivalent to that of other COVID-19 vaccines that have demonstrated protection against severe disease.

Newsbeep

The trial, which involved 2,026 people of whom half formed the placebo group, has not been peer-reviewed, the FT said.

While thousands of individual changes have arisen as the virus mutates into new variants, only a tiny minority are likely to be important or change the virus in an appreciable way, according to the British Medical Journal.

“Oxford University and AstraZeneca have started adapting the vaccine against this variant and will advance rapidly through clinical development so that it is ready for Autumn delivery should it be needed,” the AstraZeneca spokesman said.

On Friday Oxford said their vaccine has similar efficacy against the British coronavirus variant as it does to the previously circulating variants.

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)



Source link

38 Comments

  1. idn poker February 7, 2021
  2. news February 7, 2021
  3. Dưỡng Da February 7, 2021
  4. homepage February 7, 2021
  5. googueDef February 9, 2021
  6. Smisttofs February 12, 2021
  7. Croffeave February 20, 2021
  8. Croffeave February 20, 2021
  9. Croffeave February 21, 2021
  10. Croffeave February 21, 2021
  11. psysfurdy February 24, 2021
  12. fromssott February 25, 2021
  13. fromssott February 25, 2021
  14. Tofpeeddy February 27, 2021
  15. deersassy February 28, 2021
  16. deersassy February 28, 2021
  17. deersassy March 1, 2021
  18. actuapync March 2, 2021
  19. EPIDEWHOW March 5, 2021
  20. EPIDEWHOW March 6, 2021
  21. poggeld March 14, 2021
  22. poggeld March 15, 2021
  23. Advomma March 16, 2021
  24. teenilky March 18, 2021
  25. teenilky March 18, 2021
  26. Pagebact March 22, 2021
  27. Pagebact March 22, 2021
  28. Pagebact March 22, 2021
  29. Insesia March 29, 2021
  30. Insesia March 29, 2021
  31. Insesia March 29, 2021
  32. Insesia March 30, 2021
  33. Insesia March 31, 2021

Leave a Reply